NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study
Introduction and Objectives: Chronic hepatitis B (CHB) may progress to more serious liver diseases and it is often accompanied by non-alcoholic fatty liver disease (NAFLD). NAFLD and CHB share risk factors for liver fibrosis and cirrhosis, but the influence of NAFLD on fibrosis progression is contro...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Annals of Hepatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268123002582 |
| _version_ | 1827791752763801600 |
|---|---|
| author | Renling Yao Sufang Lu Ruifei Xue Jian Wang Yuanwang Qiu Yuxin Chen Jiacheng Liu Li Zhu Jie Zhan Suling Jiang Shengxia Yin Xin Tong Weimao Ding Jie Li Chuanwu Zhu Rui Huang Chao Wu |
| author_facet | Renling Yao Sufang Lu Ruifei Xue Jian Wang Yuanwang Qiu Yuxin Chen Jiacheng Liu Li Zhu Jie Zhan Suling Jiang Shengxia Yin Xin Tong Weimao Ding Jie Li Chuanwu Zhu Rui Huang Chao Wu |
| author_sort | Renling Yao |
| collection | DOAJ |
| description | Introduction and Objectives: Chronic hepatitis B (CHB) may progress to more serious liver diseases and it is often accompanied by non-alcoholic fatty liver disease (NAFLD). NAFLD and CHB share risk factors for liver fibrosis and cirrhosis, but the influence of NAFLD on fibrosis progression is controversial. This retrospective study evaluated the prevalence of NAFLD in patients with CHB and investigated associations between NAFLD and liver fibrosis in a large multi-center cohort of hepatitis B patients submitted to liver biopsy. Patients and Methods: Treatment-naïve patients with CHB who underwent liver biopsy were analyzed. Propensity score matching (PSM) was performed to adjust the confounders between patients with and without NAFLD. Results: A total of 1496 CHB patients were included. Two hundred and ninety (19.4%) patients were diagnosed with NAFLD by liver biopsy. The proportions of significant liver fibrosis (52.8% vs. 63.9%, P<0.001), advanced liver fibrosis (27.2% vs. 36.5%, P=0.003), and cirrhosis (13.4% vs. 19.7%, P=0.013) was considerably lower in CHB patients with NAFLD compared to those without NAFLD. 273 patients were included in each group after PSM adjusted for age, sex, hepatitis B envelope antigen status, and hepatitis B virus DNA. Liver fibrosis remained less severe in CHB patients with NAFLD than those without NAFLD (P<0.05) after PSM. The presence of NAFLD was considered an independent negative factor of significant liver fibrosis (odds ratio (OR) 0.692, P=0.013) and advanced liver fibrosis (OR 0.533, P = 0.002) in CHB patients. Conclusions: NAFLD is not uncommon in CHB patients with the prevalence of 19.4%. The presence of NAFLD is associated with less severe liver fibrosis in CHB patients. Registration No. of the study/trial: NCT03097952. |
| first_indexed | 2024-03-11T17:51:20Z |
| format | Article |
| id | doaj.art-cacfeab571974bd8820fb96b0c17edb3 |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-03-11T17:51:20Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-cacfeab571974bd8820fb96b0c17edb32023-10-18T04:30:34ZengElsevierAnnals of Hepatology1665-26812024-01-01291101155NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective studyRenling Yao0Sufang Lu1Ruifei Xue2Jian Wang3Yuanwang Qiu4Yuxin Chen5Jiacheng Liu6Li Zhu7Jie Zhan8Suling Jiang9Shengxia Yin10Xin Tong11Weimao Ding12Jie Li13Chuanwu Zhu14Rui Huang15Chao Wu16Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, ChinaDepartment of Infectious Diseases, The Fifth People's Hospital of Wuxi, Wuxi, Jiangsu, ChinaDepartment of Laboratory Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, ChinaDepartment of Infectious Diseases, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, Jiangsu, ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, ChinaDepartment of Hepatology, Huai'an No. 4 People's Hospital, Huai'an, Jiangsu, ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, ChinaDepartment of Infectious Diseases, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, Jiangsu, China; Corresponding authors. E-mail addresses: dr.wu@nju.edu.cn (C. Wu), doctor_hr@126.com (Rui Huang) and zhuchw@126.com (C. Zhu).Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China; Corresponding authors. E-mail addresses: dr.wu@nju.edu.cn (C. Wu), doctor_hr@126.com (Rui Huang) and zhuchw@126.com (C. Zhu).Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China; Corresponding authors. E-mail addresses: dr.wu@nju.edu.cn (C. Wu), doctor_hr@126.com (Rui Huang) and zhuchw@126.com (C. Zhu).Introduction and Objectives: Chronic hepatitis B (CHB) may progress to more serious liver diseases and it is often accompanied by non-alcoholic fatty liver disease (NAFLD). NAFLD and CHB share risk factors for liver fibrosis and cirrhosis, but the influence of NAFLD on fibrosis progression is controversial. This retrospective study evaluated the prevalence of NAFLD in patients with CHB and investigated associations between NAFLD and liver fibrosis in a large multi-center cohort of hepatitis B patients submitted to liver biopsy. Patients and Methods: Treatment-naïve patients with CHB who underwent liver biopsy were analyzed. Propensity score matching (PSM) was performed to adjust the confounders between patients with and without NAFLD. Results: A total of 1496 CHB patients were included. Two hundred and ninety (19.4%) patients were diagnosed with NAFLD by liver biopsy. The proportions of significant liver fibrosis (52.8% vs. 63.9%, P<0.001), advanced liver fibrosis (27.2% vs. 36.5%, P=0.003), and cirrhosis (13.4% vs. 19.7%, P=0.013) was considerably lower in CHB patients with NAFLD compared to those without NAFLD. 273 patients were included in each group after PSM adjusted for age, sex, hepatitis B envelope antigen status, and hepatitis B virus DNA. Liver fibrosis remained less severe in CHB patients with NAFLD than those without NAFLD (P<0.05) after PSM. The presence of NAFLD was considered an independent negative factor of significant liver fibrosis (odds ratio (OR) 0.692, P=0.013) and advanced liver fibrosis (OR 0.533, P = 0.002) in CHB patients. Conclusions: NAFLD is not uncommon in CHB patients with the prevalence of 19.4%. The presence of NAFLD is associated with less severe liver fibrosis in CHB patients. Registration No. of the study/trial: NCT03097952.http://www.sciencedirect.com/science/article/pii/S1665268123002582Chronic hepatitis BNonalcoholic fatty liver diseaseLiver fibrosisLiver biopsy |
| spellingShingle | Renling Yao Sufang Lu Ruifei Xue Jian Wang Yuanwang Qiu Yuxin Chen Jiacheng Liu Li Zhu Jie Zhan Suling Jiang Shengxia Yin Xin Tong Weimao Ding Jie Li Chuanwu Zhu Rui Huang Chao Wu NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study Annals of Hepatology Chronic hepatitis B Nonalcoholic fatty liver disease Liver fibrosis Liver biopsy |
| title | NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study |
| title_full | NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study |
| title_fullStr | NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study |
| title_full_unstemmed | NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study |
| title_short | NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study |
| title_sort | nafld is associated with less severe liver fibrosis in chronic hepatitis b a multi center retrospective study |
| topic | Chronic hepatitis B Nonalcoholic fatty liver disease Liver fibrosis Liver biopsy |
| url | http://www.sciencedirect.com/science/article/pii/S1665268123002582 |
| work_keys_str_mv | AT renlingyao nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy AT sufanglu nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy AT ruifeixue nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy AT jianwang nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy AT yuanwangqiu nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy AT yuxinchen nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy AT jiachengliu nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy AT lizhu nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy AT jiezhan nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy AT sulingjiang nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy AT shengxiayin nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy AT xintong nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy AT weimaoding nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy AT jieli nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy AT chuanwuzhu nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy AT ruihuang nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy AT chaowu nafldisassociatedwithlesssevereliverfibrosisinchronichepatitisbamulticenterretrospectivestudy |